In his presentation at Ending Age-Related Diseases 2020, investor Sergey Young discussed the potential of a trillion-dollar market, proactive versus reactive medicine, demographic changes throughout the world, technology integration, the potential of regenerative medicine, the role of capital in rejuvenation biotechnology, and many other related topics.
HELP SPREAD THE WORD
Please connect with us on social media, like and share our content, and help us build grass-roots support for healthy life extension:
On this episode of Lifespan News, Ryan O’Shea talks about how one of the market’s biggest players is putting forward money to fight against aging. Script We first told you about whispers of the Jeff Bezos-backed longevity company Altos […]
Scientists publishing in Nature Aging have shown that telomerase reverse transcriptase slows neurodegeneration but not due to its telomere-building activity […]
Hosted by Dr. Oliver Medvedik, Journal Club returns on Tuesday 25th January at 12:00 Eastern and will be broadcast live on the Lifespan.io Facebook page. […]
Dr. Leon Peshkin talks us through a new open access research tool he has helped to develop and which is free for researchers to use now. If a drug increases […]
Researchers publishing in Experimental Eye Research have discovered that the peptide aB-crystallin can reduce the cellular senescence that affects the progression of age-related macular degeneration (AMD). What is αB-crystallin? αB-crystallin is a well-known […]
In September 2021, we reported that Altos Labs was about to launch an ambitious project to develop partial cellular reprogramming to the point where […]
In his talk at Ending Age-Related Diseases 2021, João Pedro de Magalhães discussed the difference between longevity and rejuvenation along with the need for more […]
A study published in Frontiers in Aging Neuroscience examined the relationship between epigenetic age acceleration and hearing [1]. Since 1958, a team of researchers from the National Institute on Aging […]
Write a comment: